Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001558370-17-006054
Filing Date
2017-08-07
Accepted
2017-08-07 08:07:14
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B3 f424b3.htm 424B3 10783
2 GRAPHIC f424b3g001.jpg GRAPHIC 4655
  Complete submission text file 0001558370-17-006054.txt   18338
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

EIN.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-217296 | Film No.: 171010112
SIC: 2834 Pharmaceutical Preparations